EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future

Nadine Rouphael iD, Mary Bausch-Jurken

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiad162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Nadine Rouphael und 1 weiteren Autor:innen. Beteiligte Einrichtung: Divison of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease affects more than 800 million people worldwide and often progresses to end-stage renal disease, which requires maintenance dialysis. Patients receiving dialysis are at higher risk for severe respiratory infections, including SARS-CoV-2 (the causative agent of COVID-19). In addition, many patients who receive dialysis also receive immunosuppressive treatments for conditions such as systemic vasculitis, systemic lupus erythematosus, or malignancies. Many studies have shown that while mRNA COVID-19 vaccines induce some level of immune response in patients receiving dialysis, the magnitude of response is often lower than that of healthy individuals, and responses rapidly wane. Importantly, the risk of COVID-19–related hospitalization and mortality for patients receiving dialysis is 4- to 8-fold higher compared with the general population. In this article, we summarize recent immunogenicity and real-world outcomes of COVID-19 mRNA vaccination among patients receiving dialysis, with a focus on the 3-dose extended primary series and additional (fourth) doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19HumansSARS-CoV-2Renal Replacement TherapyVaccinationImmunityRNA, MessengerAntibodies, Viral

Stichwörter der Autor:innen

COVID-19SARS-CoV-2dialysisimmunocompromisedmRNA vaccinerenal replacement therapy

Substanzen

COVID-19 VaccinesRNA, MessengerAntibodies, Viral

Autor:innen und Institutionen

  • Divison of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Moderna, Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Nadine Rouphael

Förderung

  • Moderna, Inc

Zitieren

APA

Rouphael, N., & Bausch-Jurken, M. (2023). COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad162

Vancouver

Rouphael N, Bausch-Jurken M. COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad162

BibTeX
@article{Rouphael2023,
  author = {Rouphael, Nadine and Bausch-Jurken, Mary},
  title = {COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiad162}
}
Kostenlos starten →